See more : Trajan Group Holdings Limited (TRJ.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Cibus, Inc. (CBUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cibus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fast Radius, Inc. (FSRDQ) Income Statement Analysis – Financial Results
- Chaoprayamahanakorn Public Company Limited (CMC.BK) Income Statement Analysis – Financial Results
- XP Inc. (XPVVV) Income Statement Analysis – Financial Results
- Norfolk Southern Corporation (NSC) Income Statement Analysis – Financial Results
- Strong Global Entertainment, Inc. (SGE) Income Statement Analysis – Financial Results
Cibus, Inc. (CBUS)
About Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.82M | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 395.00K | 1.53M | 28.56M | 35.13M | 9.28M | 1.08M | 551.00K | 200.00K | 751.00K |
| Gross Profit | 1.42M | -1.38M | -2.57M | -11.28M | -1.98M | -845.00K | -43.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 78.26% | -877.07% | -9.89% | -47.28% | -27.19% | -358.05% | -8.46% | 49.87% | 40.96% |
| Research & Development | 42.37M | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.91M | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 249.02M | 5.57M | 19.00K | -126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 320.31M | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 320.70M | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 527.00K | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.89M | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 4.69M | 1.53M | 2.34M | 1.87M | 1.61M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -314.59M | -15.21M | -25.43M | -41.53M | -36.52M | -25.56M | -25.43M | -11.74M | -5.48M |
| EBITDA Ratio | -17,313.43% | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,810.59% | -4,968.11% | -2,948.37% | -445.52% |
| Operating Income | -318.88M | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -17,549.97% | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | -18.76M | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -337.64M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -18,582.44% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -4.00K | -1.45M | -114.00K | 1.56M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Net Income | -267.63M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -14,729.06% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| EPS Diluted | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| Weighted Avg Shares Out | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
| Weighted Avg Shares Out (Dil) | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
Cibus to Participate in Upcoming June Investor Events
SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced its participation in the following June investor events.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cibus, Inc. (CBUS) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) investors concerning the Company's possible violations of federal securities laws. On June 4, 2024, Bonitas Research published a...
The Law Offices of Frank R. Cruz Announces Investigation of Cibus, Inc. (CBUS) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who...
Cibus Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm
Cibus, Inc. investigated for potential securities law violations. Investors who have lost money in their Cibus investment should contact Block & Leviton.
Breaking News: Johnson Fistel, LLP Investigates Cibus Following Short Report
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Cibus, Inc. (NASDAQ: CBUS). We are looking into whether the Company or its executives failed to disclose...
Canada Added to a Growing List of Countries Regulating Cibus' Gene Editing Technologies Similar to Conventional Breeding
Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing Cibus Applauds the Canadian Food Inspection Agency's (CFIA) New Guidelines for Plants Developed Using Gene Editing
Cibus, Inc. (CBUS) Q1 2024 Earnings Call Transcript
Cibus, Inc. (NASDAQ:CBUS ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Wade King - Chief Financial Officer Rory Riggs - Co-Founder, Chief Executive Officer and Chairman Peter Beetham - Co-Founder, President and Chief Operating...
Cibus (CBUS) Reports Q1 Loss, Tops Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $5.45 per share a year ago.
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report...
Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates (Revised)
Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports